Last reviewed · How we verify
Panitumumab plus GEMOX chemotherapy — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Panitumumab plus GEMOX chemotherapy (Panitumumab plus GEMOX chemotherapy) — Prof. Massimo Aglietta.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Panitumumab plus GEMOX chemotherapy TARGET | Panitumumab plus GEMOX chemotherapy | Prof. Massimo Aglietta | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Panitumumab plus GEMOX chemotherapy CI watch — RSS
- Panitumumab plus GEMOX chemotherapy CI watch — Atom
- Panitumumab plus GEMOX chemotherapy CI watch — JSON
- Panitumumab plus GEMOX chemotherapy alone — RSS
Cite this brief
Drug Landscape (2026). Panitumumab plus GEMOX chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/panitumumab-plus-gemox-chemotherapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab